Brokerages Anticipate CEL-SCI Co. (NYSE:CVM) Will Announce Earnings of -$0.16 Per Share

Wall Street analysts forecast that CEL-SCI Co. (NYSE:CVMGet Rating) will announce earnings of ($0.16) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for CEL-SCI’s earnings. CEL-SCI reported earnings of ($0.20) per share in the same quarter last year, which would suggest a positive year over year growth rate of 20%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that CEL-SCI will report full-year earnings of ($0.49) per share for the current year. For the next financial year, analysts anticipate that the firm will post earnings of $0.91 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow CEL-SCI.

Separately, started coverage on CEL-SCI in a report on Thursday, March 31st. They issued a “sell” rating on the stock.

Shares of CVM stock traded down $0.43 during trading hours on Tuesday, reaching $3.24. The company’s stock had a trading volume of 177,484 shares, compared to its average volume of 1,388,992. The company’s 50 day moving average is $4.68. The firm has a market capitalization of $140.21 million, a P/E ratio of -3.55 and a beta of 2.06. CEL-SCI has a fifty-two week low of $3.15 and a fifty-two week high of $27.86. The company has a quick ratio of 11.94, a current ratio of 12.56 and a debt-to-equity ratio of 0.25.

CEL-SCI Company Profile (Get Rating)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Featured Articles

Get a free copy of the Zacks research report on CEL-SCI (CVM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with's FREE daily email newsletter.